JP2017536343A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536343A5
JP2017536343A5 JP2017518929A JP2017518929A JP2017536343A5 JP 2017536343 A5 JP2017536343 A5 JP 2017536343A5 JP 2017518929 A JP2017518929 A JP 2017518929A JP 2017518929 A JP2017518929 A JP 2017518929A JP 2017536343 A5 JP2017536343 A5 JP 2017536343A5
Authority
JP
Japan
Prior art keywords
amino
carboxy
butanoyl
ethoxy
glp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017518929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/073372 external-priority patent/WO2016055610A1/en
Publication of JP2017536343A publication Critical patent/JP2017536343A/ja
Publication of JP2017536343A5 publication Critical patent/JP2017536343A5/ja
Withdrawn legal-status Critical Current

Links

JP2017518929A 2014-10-10 2015-10-09 安定したglp−1ベースのglp−1/グルカゴン受容体コアゴニスト Withdrawn JP2017536343A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188421.3 2014-10-10
EP14188421 2014-10-10
PCT/EP2015/073372 WO2016055610A1 (en) 2014-10-10 2015-10-09 Stable glp-1 based glp-1/glucagon receptor co-agonists

Publications (2)

Publication Number Publication Date
JP2017536343A JP2017536343A (ja) 2017-12-07
JP2017536343A5 true JP2017536343A5 (enExample) 2018-11-08

Family

ID=51663097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518929A Withdrawn JP2017536343A (ja) 2014-10-10 2015-10-09 安定したglp−1ベースのglp−1/グルカゴン受容体コアゴニスト

Country Status (7)

Country Link
US (1) US9988430B2 (enExample)
EP (1) EP3204408B1 (enExample)
JP (1) JP2017536343A (enExample)
CN (1) CN107108713A (enExample)
ES (1) ES2805326T3 (enExample)
TW (1) TW201629095A (enExample)
WO (1) WO2016055610A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重glp1/gipまたは三方glp1/gip/グルカゴンアゴニストとしてのエキセンジン−4誘導体
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
KR102706686B1 (ko) 2016-05-06 2024-09-19 아이오니스 파마수티컬즈, 인코포레이티드 Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
SG11202000135PA (en) * 2017-07-13 2020-02-27 Fuji Oil Holdings Inc Peptide
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
CN115536739B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
EP2068910A2 (en) * 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN102075337A (zh) 2009-11-20 2011-05-25 腾讯科技(深圳)有限公司 一种即时通信消息显示方法和相关装置
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EA026384B1 (ru) 2010-01-20 2017-04-28 Зилэнд Фарма А/С Лечение заболеваний сердца
EP2552950A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
KR20130086343A (ko) * 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
MY167234A (en) * 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
CA2939763A1 (en) 2014-02-18 2015-08-27 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia

Similar Documents

Publication Publication Date Title
JP2016526012A5 (enExample)
RU2015146600A (ru) Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
JP2012529463A5 (enExample)
ES2887370T3 (es) Nuevo agonista del receptor de amilina y calcitonina
RU2434019C2 (ru) Ацилированные glp-1 соединения
JP6121330B2 (ja) 作用持続時間が増した改変ポリペプチド
JP2016531156A5 (enExample)
JP2008533105A5 (enExample)
KR102302634B1 (ko) 변형된 치료제 및 이의 조성물
RU2550696C2 (ru) Основанные на амидах пролекарства пептидов глюкагонового надсемейства
JP6054861B2 (ja) 新規のグルカゴン類似体
JP6572497B2 (ja) 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
JP2018505146A5 (enExample)
JP2013533849A5 (enExample)
JP2012512903A5 (enExample)
JP2012506402A5 (enExample)
CA2797089A1 (en) Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
JP2014527975A5 (enExample)
JP2013518115A5 (enExample)
JP2011502159A5 (enExample)
RU99106518A (ru) Glp-1 производные
JP2017502024A5 (enExample)
JP2012518035A5 (enExample)
JP2022509568A5 (enExample)
JP2013523619A5 (enExample)